Wednesday, October 1, 2014

Tuesday Features

In conversation with Pivotal Therapeutics

In conversation with Pivotal Therapeutics

BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular disease (CVD) patients, an under-recognized, yet highly prevalent condition. The team, including Eugene Bortoluzzi, CEO, Dr. George Jackowski, CSO, Rachelle... [Read more of this feature]


Amarantus on road to commercializing AD test

Amarantus on road to commercializing AD test

Amarantus Bioscience Holdings’ (OTCQB:AMBS) master services agreement with the lab services arm of ICON (NASDAQ:ICLR) puts Amarantus on the road to commercializing its LymPro diagnostic blood test for the early detection of Alzheimer’s disease (AD). Gerald Commissiong “This agreement represents a major milestone, as we can now prepare LymPro... [Read more of this feature]


Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to emphasize that this is not guidance, but within five years, we want our dermatology business in Canada to grow from $2-million this year to $50-million,... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Verisante begins FDA approval process for Aura

Verisante begins FDA approval process for Aura

Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has initiated communications with the FDA for the approval of Aura, a device for the detection of skin cancer. “Verisante has now submitted documents to the FDA as we begin the formal application process for approval to market and sell Aura in the U.S.,” president and CEO, Thomas Braun, said... [Read more of this brief]


Cipher licensee launches new dosages of Absorica in U.S.


Cipher licensee launches new dosages of Absorica in U.S.


Cipher Pharmaceuticals’ (OTCBB:CPHMF; TSX:DND) licensee, Ranbaxy Laboratories, has launched Absorica (isotretinoin) 25 mg and 35 mg capsules into the U.S. health care market. Absorica has become the most prescribed branded oral isotretinoin in the U.S., according to a recent independent survey of dermatologists. The product is indicated for the treatment... [Read more of this brief]


Verisante renegotiates LOI for Core technology

Verisante renegotiates LOI for Core technology

Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has renegotiated a letter of intent with a strategic partner in China. Under the new accord, Verisante will enter into a definitive agreement to sublicense the world-wide rights to develop and commercialize the Core Raman technology, with the ClearVu endoscopic camera system, for the detection of lung cancer,... [Read more of this brief]


NOVADAQ to supply SerenaGroup with LUNA

NOVADAQ to supply SerenaGroup with LUNA

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into a partnership agreement to supply SerenaGroup of Cambridge, Mass. with multiple LUNA fluorescence angiography systems. SerenaGroup operates wound and hyperbaric centers throughout the U.S. and is a global leader in wound healing research. The LUNA system is designed for use in outpatient... [Read more of this brief]


Amarantus requests pre-IND feedback from FDA

Amarantus requests pre-IND feedback from FDA

Amarantus Bioscience Holdings (OTCQB:AMBS) has submitted a request to the FDA for a review and written feedback of the Phase 2b clinical trial design for Eltoprazine in levodopa-induced dyskinesia (LID), a common side effect of levodopa treatment in Parkinson’s disease patients. ”We are very pleased to have submitted this pre-IND review... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+